Beyondspring (BYSI) PT Set at $52.00 by Maxim Group
Beyondspring (NASDAQ:BYSI) received a $52.00 price objective from equities researchers at Maxim Group in a note issued to investors on Thursday. The firm currently has a “buy” rating on the stock. Maxim Group’s price target suggests a potential upside of 68.50% from the stock’s current price.
The analysts wrote, “BeyondSpring announced that Pliabulin has met its primary endpoint in the P2 portion of its global Phase 2/3 clinical trial (Study 105) for the prevention of CIN with docetaxel. In addition, the company announced that a p value of < 0.0001 from its ongoing Phase 3 NSCLC clinical trial (Study 103) was achieved from 138 patients on a secondary endpoint of grade 4 neutropenia, which demonstrates Plinabulin’s ability to reduce docetaxel CIN. Interim anti-cancer efficacy data from Study 103 is expected in mid-2018."”
A number of other research analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Beyondspring in a research note on Monday, August 21st. Zacks Investment Research lowered shares of Beyondspring from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Finally, Seaport Global Securities assumed coverage on shares of Beyondspring in a research note on Tuesday, December 5th. They set a “buy” rating and a $56.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $54.50.
Beyondspring (NASDAQ:BYSI) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. research analysts predict that Beyondspring will post -4.43 EPS for the current year.
An institutional investor recently bought a new position in Beyondspring stock. Tanaka Capital Management Inc. purchased a new stake in Beyondspring Inc (NASDAQ:BYSI) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring comprises 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned approximately 0.10% of Beyondspring at the end of the most recent quarter. 1.22% of the stock is currently owned by institutional investors.
Beyondspring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.